BNP Paribas Financial Markets Takes Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

BNP Paribas Financial Markets purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 12,490 shares of the company’s stock, valued at approximately $92,000.

A number of other large investors have also made changes to their positions in the stock. Jane Street Group LLC increased its holdings in shares of Vir Biotechnology by 9.8% in the 4th quarter. Jane Street Group LLC now owns 143,077 shares of the company’s stock valued at $1,050,000 after purchasing an additional 12,730 shares in the last quarter. Northern Trust Corp raised its position in Vir Biotechnology by 5.9% during the fourth quarter. Northern Trust Corp now owns 930,454 shares of the company’s stock worth $6,830,000 after acquiring an additional 51,530 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Vir Biotechnology during the fourth quarter worth about $1,477,000. Nebula Research & Development LLC acquired a new position in Vir Biotechnology during the fourth quarter worth about $84,000. Finally, Syon Capital LLC acquired a new position in Vir Biotechnology during the fourth quarter worth about $77,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, CEO Backer Marianne De sold 79,712 shares of the business’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now directly owns 769,505 shares in the company, valued at $4,578,554.75. The trade was a 9.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is owned by insiders.

Vir Biotechnology Stock Performance

Vir Biotechnology stock opened at $4.86 on Monday. Vir Biotechnology, Inc. has a 1 year low of $4.32 and a 1 year high of $14.45. The firm has a 50 day moving average price of $5.50 and a 200 day moving average price of $7.50. The company has a market cap of $671.84 million, a price-to-earnings ratio of -1.24 and a beta of 1.36.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $3.03 million during the quarter, compared to analysts’ expectations of $8.59 million. During the same quarter in the previous year, the firm posted ($0.48) earnings per share. Vir Biotechnology’s revenue for the quarter was down 94.6% compared to the same quarter last year. Sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group cut their price objective on shares of Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research report on Thursday, May 22nd. Finally, Barclays boosted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).